跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MYLAN-RIVASTIGMINE PATCH 5 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MYLAN-RIVASTIGMINE PATCH 5
Authorized
STANDARD
MYLAN-RIVASTIGMINE PATCH 5
Mylan Pharmaceuticals ULC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3858e5f128f7619a
Company
Mylan Pharmaceuticals ULC
Type
Standard
Approval Details
Approval Id
3858e5f128f7619a
Drug Approval Canada Name
MYLAN-RIVASTIGMINE PATCH 5
Product Name
MYLAN-RIVASTIGMINE PATCH 5
Status
Marketed
Status Date
2016-12-05
Original Market Date
2016-12-05
Din
02423413
Drug Class
Human
Dosage Form
Patch
Route Of Administration
Transdermal
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521007
Company Name
Mylan Pharmaceuticals ULC
Company Address
85 Advance Road, Etobicoke, Ontario, Canada, M8Z 2S6
Active Ingredients
RIVASTIGMINE
4.6 MG / 24 HOUR
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3858e5f128f7619a
Type
Standard
Back to Health Canada Approvals